BioVie Inc
@BioVie_Pharma
Followers
282
Following
39
Media
65
Statuses
130
At BioVie we believe that every person deserves to live free from the limitations of aging and disease.
USA
Joined June 2023
A reminder to join us tomorrow for a live webinar with our CEO, Cuong Do, discussing bezisterim for the treatment of neurological & neurodegenerative diseases. Register here: https://t.co/u2Bz5k6sBK
#Inflammation #InsulinResistance #Alzheimers #Parkinsons #LongCOVID $BIVI
0
1
2
Our CEO, Cuong Do, will share updates on bezisterim for the treatment of neurological & neurodegenerative diseases during a live webinar on October 8. Register here: https://t.co/u2Bz5k5UMc
#Neuroinflammation #InsulinResistance
#Alzheimers #Parkinsons #LongCOVID $BIVI
0
2
5
On #WorldAlzheimersDay, we recognize the nearly 60M people worldwide living w/ Alzheimer’s & other forms of dementia. We're committed to advancing the science of #neuroinflammation -a root cause of #Alzheimer’s, #Parkinson’s & other diseases of #aging. #InsulinResistance $BIVI
1
0
1
Our CEO, Cuong Do, recently joined @ThatKevinShow to share an update on the clinical trials of bezisterim for patients with #Parkinson’s disease & #LongCOVID. Listen here: https://t.co/UOnOoy5C5y
#Neuroinflammation #InsulinResistance #Aging #ClinicalTrials #Neurology $BIVI
0
2
3
We presented the ADDRESS-LC P2 trial design of our ongoing study exploring bezisterim to treat #neurological symptoms at the #LongCOVID @KeystoneSymp. Learn more: https://t.co/3is7q5b3Qm
#BrainFog #Fatigue #Neuroinflammation #KSLongCOVID26 $BIVI
1
4
9
We closed the sale of our previously announced underwritten public offering, with total gross proceeds of $12M. Funds will support $BIVI through BOTH P2 data readouts of bezisterim in #Parkinson’s & #LongCOVID. https://t.co/CahmPCTj60
#Neuroinflammation $BIVI
4
0
0
The role of neuroinflammation is no longer considered a peripheral component in the treatment of #Parkinson’s disease. It is central… and offers a new array of therapeutic promise. #Neuroinflammation #InsulinResistance #Neurology
Growing research is pointing to chronic #neuroinflammation as a driver of #Parkinson’s disease onset and progression, implicating potential for new treatment approaches, Dr. Mark Stacy of @MedUnivSC writes in this exclusive article. @ParkinsonDotOrg
https://t.co/YOpaeOzVLC
1
0
0
Watch! If you missed our webinar, "The ADDRESS-LC Trial: Studying the Impact of Bezisterim on Brain Fog and Fatigue in People with #LongCovid," you can now watch the recording here: https://t.co/EoonW46tj8
@biovie @MichaelPelusoMD
#clinicaltrial
0
0
0
BioVie was a poster winner at this year’s #ATMRD2025. Our CMO and lead author spoke with @neurology_live about the presentation. Watch here: https://t.co/ILz3pHM2wm
#ParkinsonsDisease #ClinicalTrials #Neuroinflammation $BIVI
neurologylive.com
A duo of experts discussed a novel hybrid trial approach combining in-home video assessments with traditional visits to improve Parkinson disease research participation and assess a new investigati...
0
1
3
We presented data that suggest bezisterim’s potential to target epigenetic-driven age deceleration as a treatment for #Alzheimers disease and other #neurodegenerative diseases of aging. Learn more: https://t.co/532hMoLrhP
#Aging #Longevitiy #Neuroscience $BIVI
0
1
1
We’re thrilled to announce the appointment of Amy S. Chappell, MD, FAAN, and Kameel D. Farag to our Board of Directors. Details: https://t.co/YDYCDLPqPY
#Biotech #Neuroinflammation #Neurology $BIVI
0
1
1
Register for “ADDRESS-LC Trial: Studying the Impact of #Bezisterim on #BrainFog & #Fatigue in People w/ #LongCovid.” We'll discuss how to join & implications for #MECFS. 7.22 @ 3 pm PT/6 pm ET https://t.co/hwpRndXYJb
1
5
16
In a keynote session today at #ARC2025, we presented data highlighting bezisterim’s potential to target epigenetic-driven age acceleration as a treatment for #Alzheimers and other #neurodegenerative diseases of aging. Learn more here: https://t.co/kFQVrNZ9ZP
#Neuroscience $BIVI
1
3
6
At #ATMRD2025, researchers presented the design of the ongoing phase 2 SUNRISE-PD trial, assessing the safety and efficacy of investigational bezisterim on motor and nonmotor symptoms in patients with early-stage #PD. @BioVie_Pharma @PMDAlliance Read More:
neurologylive.com
The design of a phase 2 study, presented at ATMRD 2025, highlighted the trial’s patient-focused approach, allowing patients with Parkinson disease to complete visits either at home or in a clinic.
0
1
1
Dr. Mark Stacy highlighted the potential of bezisterim as a treatment targeting #neuroinflammation in Parkinson's disease & its innovative P2 trial design on @PracticalNeuro’s podcast. Listen here: https://t.co/St9N6EBj1m
#ParkinsonsAwareness #BrainHealthMonth $BIVI
0
1
1
Our hybrid, decentralized trial of bezisterim (NE3107) in early Parkinson’s Disease prioritizes patient access and participation. Learn more: https://t.co/eLWpIRox9F
#ATMRD #ParkinsonsDisease #MovementDisorders $BIVI
1
2
5
We will be presenting a poster at #ATMRD highlighting the decentralized design of our Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson’s disease. Learn more: https://t.co/gjYYUZyMTK
#ParkinsonsDisease #MovementDisorders $BIVI
0
1
2
A new #LongCovid clinical trial is enrolling for bezisterim, an investigational anti-inflammatory drug that crosses the blood-brain barrier. It has been studied in neurological & neurodegenerative disorders, including Alzheimer’s & Parkinson’s. 1/
11
83
238
We’re enrolling a new trial for bezisterim to address these symptoms: https://t.co/mexfJASFYP
#BrainAwarenessMonth #NeuroCOVID
0
0
0